Reduction of urinary basic fibroblast growth factor using pentosan polysulphate sodium

Br J Urol. 1996 Jul;78(1):54-6. doi: 10.1046/j.1464-410x.1996.05710.x.


Objective: To evaluate the use of pentosan polysulphate sodium (PPS) to reduce the level of urinary basic fibroblast growth factor (bFGF).

Patients and methods: Forty-one patients with a clam enterocystoplasty were randomized to receive either 200 mg three times daily of oral PPS (n = 21) or placebo (n = 20) for 6 weeks. Three patients acted as a cross-over study. Urinary bFGF was measured before and after treatment and the degree of symptomatic benefit assessed using a questionnaire.

Results: There was no reduction in bFGF in the patients receiving placebo (P = 0.235) but there was a statistically significant reduction in bFGF (P = 0.0251) in the patients receiving PPS, most of whom were symptomatically improved, especially with regard to mucus production.

Conclusion: PPS may have a role in reducing urinary bFGF in patients with bladder tumours or following an enterocystoplasty and also in improving the quality of life of patients with a clam enterocystoplasty.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Adolescent
  • Adult
  • Anticoagulants / therapeutic use*
  • Child
  • Cross-Over Studies
  • Female
  • Fibroblast Growth Factor 2 / urine*
  • Humans
  • Male
  • Middle Aged
  • Pentosan Sulfuric Polyester / therapeutic use*
  • Postoperative Care
  • Urinary Bladder Neoplasms / surgery


  • Anticoagulants
  • Fibroblast Growth Factor 2
  • Pentosan Sulfuric Polyester